Integrated and translational nonclinical in vivo cardiovascular risk assessment: Gaps and opportunities

Integrated and translational nonclinical in vivo cardiovascular risk assessment: Gaps and opportunities

► Nonclinical CV safety testing paradigms may not adequately model complex patient populations. ► Holistic and predictive approach needed to understand long term nonclinical and clinical risks. ► Better understanding of concordance of animal models and clinical patients needed. ► Tools and technolog...

Full description

Saved in:
Bibliographic Details
Published in:Regulatory toxicology and pharmacology Vol. 65; no. 1; pp. 38 - 46
Main Authors: Berridge, Brian R., Hoffmann, Peter, Turk, James R., Sellke, Frank, Gintant, Gary, Hirkaler, Gerald, Dreher, Kevin, Schultze, A. Eric, Walker, Dana, Edmunds, Nick, Halpern, Wendy, Falls, James, Sanders, Marty, Pettit, Syril D.
Format: Journal Article
Language:English
Published: Netherlands Elsevier Inc 01-02-2013
Subjects:
Animals
Cardiotoxicity
Cardiovascular Diseases - chemically induced
Cardiovascular safety
Disease Models, Animal
Drug Design
Drug Industry - methods
Drug-Related Side Effects and Adverse Reactions
Endpoint Determination
Humans
MicroRNAs - metabolism
Nonclinical safety
Research Design
Risk Assessment - methods
Safety assessment
Species Specificity
Nonclinical safety
Cardiotoxicity
Safety assessment
Cardiovascular safety
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:► Nonclinical CV safety testing paradigms may not adequately model complex patient populations. ► Holistic and predictive approach needed to understand long term nonclinical and clinical risks. ► Better understanding of concordance of animal models and clinical patients needed. ► Tools and technologies are available that could improve nonclinical modeling of clinical CV risk. Cardiovascular (CV) safety concerns are a significant source of drug development attrition in the pharmaceutical industry today. Though current nonclinical testing paradigms have largely prevented catastrophic CV events in Phase I studies, many challenges relating to the inability of current nonclinical safety testing strategies to model patient outcomes persist. Contemporary approaches include a spectrum of evaluations of CV structure and function in a variety of laboratory animal species. These approaches might be improved with a more holistic integration of these evaluations in repeat-dose studies, addition of novel endpoints with greater sensitivity and translational application, and use of more relevant animal models. Particular opportunities present with advances in imaging capabilities applicable to rodent and non-rodent species, technical capabilities for measuring CV function in repeat-dose animal studies, detection and quantitation of microRNAs and wider use of alternative animal models. Strategic application of these novel opportunities considering putative CV risk associated with the molecular drug target as well as inherent risks present in the target patient population could tailor or ‘personalize’ nonclinical safety assessment as a more translational evaluation. This paper is a call to action for the clinical and nonclinical drug safety communities to assess these opportunities to determine their utility in filling potential gaps in our current cardiovascular safety testing paradigms.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0273-2300
1096-0295
DOI:10.1016/j.yrtph.2012.09.007